Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment

Full text
Primi, Marina Candido [1] ; Maltarollo, Vinicius Goncalves [1] ; Magalhaes, Juliana Gallottini [1] ; de Sa, Matheus Malta [2] ; Rangel-Yagui, Carlota Oliveira [3] ; Goulart Trossini, Gustavo Henrique [1]
Total Authors: 6
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, BR-05508 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet & Mol Cardiol, BR-05508 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Biochem & Pharmaceut Technol, BR-05508 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Journal of Enzyme Inhibition and Medicinal Chemistry; v. 31, n. 2, p. 283-294, MAR 3 2016.
Web of Science Citations: 2

The dopamine hypothesis states that decreased dopaminergic neurotransmission reduces schizophrenia symptoms. Neurokinin-3 receptor (NK3) antagonists reduce dopamine release and have shown positive effects in pre-clinical and clinical trials. We employed 2D and 3D-QSAR analysis on a series of 40 non-peptide NK3 antagonists. Multivariate statistical analysis, PCA and HCA, were performed to rational training/test set splitting and PLS regression was employed to construct all QSAR models. We constructed one highly predictive CoMFA model (q(2)=0.810 and r(2)=0.929) and acceptable HQSAR and CoMSIA models (HQSAR q(2)=0.644 and r(2)=0.910; CoMSIA q(2)=0.691, r(2)=0.911). The three different techniques provided convergent physicochemical results. All models indicate cyclopropane, piperidine and di-chloro-phenyl ring attached to cyclopropane ring and also the amide group attached to the piperidine ring could play an important role in ligand-receptor interactions. These findings may contribute to develop potential NK3 receptor antagonists for schizophrenia. (AU)

FAPESP's process: 13/15947-3 - New antituberculosis agents candidates: design and synthesis of phosphopantetheine adenylyltransferase inhibitors
Grantee:Marina Candido Primi
Support Opportunities: Scholarships in Brazil - Doctorate